The objective of this study was to determine the clinical presentation of GTD and response of GTN to single and multiple agent chemotherapy on the basis of WHO Prognostic risk scoring system.
INTRODUCTION
Gestational trophoblastic disease (GTD) describes a rare and highly curable group of tumour pathology that arises from tissues of placental origin and results from abnormal conception caused by aberrant fertilization. 1 Most of the GTD cases include two types of hydatidiform moles (HM) that have a variable potential to progress into the rare malignant disease gestational trophoblastic neoplasia (GTN). 2, 3 GTN is among rare human tumours that can be cured, with an overall 90% of patient survival, due to the inherent chemotherapy sensitivity of trophoblastic neoplasms, the effective use of the tumour marker beta human chorionic gonadotrophin (βhCG) for diagnosis of disease and monitoring of therapy and the identification of prognostic factors that enhances individualization of chemotherapy. [1] [2] [3] [4] [5] [6] [7] The objective of this study was to determine the clinical presentation of GTD and response of GTN to single and multiple agent chemotherapy on the basis of WHO Prognostic risk scoring system.
METHODS
This was a cross-sectional retrospective study undertaken at Paropakar Maternity and Women's Hospital (PMWH). Ethical approval was taken from the hospital. The medical records of GTD were reviewed from January 25, 2015 to January 24, 2016. The charts were collected from medical record section. Data pertaining patient characteristics, histopathology types of GTD, management, prognostic risk scores, chemotherapy, follow up and remissions were retrieved and were analyzed using SPSS version 16.0.
Following suction evacuation, patients were followed up with weekly serum βhCG till three consecutive normal values, then monthly for six months.
For malignant and persistent gestational trophoblastic tumours (PGTT), WHO Prognostic Scoring System based on prognostic factors was done. (Table 1) NJOG 2017 Jan-Jun; 23 (1): 26- In all cases, the cycles were repeated after 7 days interval. The resonse to treatment was evaluated during follow-up by history, clinical examination, serum βhCG levels and imaging as and when required. When serum βhCG became normal, patient received two more cycles of respective chemotherapy.
RESULTS
During the study period, total gynaecological admissions were 3277. Of these, 102 (3.1%) were GTD cases.
Mean age of GTD cases was 25.09±7.9 years (Range:15-50 years). Parity range is P 0 -P 11 .
Characteristics of the patients are depicted in Table 2 . (Figure 1 )
Figure 1. Prognostic Risk Score in relation to age
For low risk group, chemotherapy MTX-FA was started for rising value of serum βhCG(13), plateau value(2), persistent vaginal bleeding with rising serum βhCG(2), serum βhCG not declining six months post-evacuation(1) and invasive mole(3). Among these, five were converted to Act-D for rising value of serum βhCG(4) and plateau value(1). One case converted to EMA-CO as serum βhCG began to rise by six-fold with rescoring of high risk.
A case of high risk score group received EMA-CO for increased value of serum βhCG.
Response
Out of 20 low risk cases that received MTX-FA, 13/20 (65%) achieved remission. Due to low response of MTX-FA, five of them were converted to Act-D and achieved remission(100%). Another was converted to EMA-CO with rescoring of high risk and achieved remission with four cycles.
A case of high risk score 8 who had S/E for complete mole outside hospital and was lost to F/U there, visited to this hospital 12 months following evacuation who had persistent vaginal bleeding and serum βhCG >150,000mIU/ml received EMA-CO regimen and achieved remission with eight cycles (100% remission for EMA-CO). 
Undergoing chemotherapy
One case of complete mole (low risk score 4) received MTX-FA for rising serum βhCG and completed three cycles so far. Another case of invasive mole 44 years P 10 lady underwent total abdominal hysterectomy with bilateral salpingo-ophorectomy (TAH with BSO) for persistent vaginal bleeding and not declining serum βhCG (preevacuation state >150,000 mIU/ml) following which serum βhCG declined but later increased by 2-fold, received MTX-FA (low risk score 5) completed six cycles and responding well. Both of these cases are undergoing chemotherapy and F/U. Those converted received Act-D by three patients two cycles each, one cycle by one patient and another one received five cycles.
There was one patient who received five MTX-FA cycles and converted to EMA-CO to receive four cycles after rescoring.
There was one patient with high risk score who received eight cycles of EMA-CO.
DISCUSSION
The incidence of GTD varies greatly between different parts of the world. Asian ethnicity is an important risk factor for GTD. 9 In this study, the incidence of GTD was 3.1%. Mean age of GTD cases was 25.09±7.9 years (Range:15-50 years). Among 102 cases of GTD, range of parity was from 0 to 11 which was comparable (0 to 17) to a study by Fatima et al. 10 In this study, most of the GTD cases presented as P/V bleeding (67.6%) which is similar to studies conducted by Fatima et al. 10 and Hou et al. 11 USG diagnosed cases of GTN in 29.4% and more than half of these,17/30 (56.6%) were diagnosed in first trimester, reflecting the diagnosis of disease by USG in early pregnancy. 12 The risk of GTN for complete HM (15-20%) is significantly higher than for partial HM (0.2-4%) [13] [14] [15] [16] as was also noted in this study CHM (15.5%) and PHM (5.5%).
Maternal age is considered as one of the high risk factors for GTN. 17 In our study, the GTN patients were 18 to 50 years of age and in a study by Fulop et al. 18 noted the age range of 14 to 53 years. In this study, out of 22 GTN cases, although majority of low risk scored were below 40 years age group (18), other two were >40 years. Under high risk group, one was 25 years and another 50 years age. (Figure 1 ) In a study conducted by Shrivastava et al., 19 eight out of 27 (29.6%) were aged above 40 years and all were scored as high risk GTN. All low risk cases were aged below 40 years.
Chemotherapy is highly effective in most patients with GTN. For nearly all low risk GTN patients, single agent chemotherapy with either MTX or Act-D is the preferred treatment. 1, 2, 5, 7, 20 A variety of regimens have been developed, in which non-randomized, mostly retrospective studies demonstrate a 50-90% chance of inducing remissiion. 21 Multiple agent chemotherapy should be used primarily in all high risk GTN patients. The most widely used regimen includes EMA-CO with cure rates ranging from 70% to 90%. 22 In this study, the remission rate of MTX for low risk GTN was 65% which is similar (66.8%) to a study conducted by McNeish et al. 23 In various other studies, MTX remission rate ranged from 81% to 96.3%. 18, 24, 25 The remission rate of Act-D is 96.4% (Fulop et al.) 18 and was 100% in this study. This rate ranged from 75% to 86.5% in different other studies. 23, 24, 26 These variations could be due to different doses used in their studies.
The remission rate of EMA-CO regimen for high risk GTN in this study was 100%. However, different studies reported 71% (Escobar et al.) , 27 87.7% (Bafna et al.) 28 and 89.4% (Shrivastava et al.) 19 which could be due to the presence of widespread metastatic disease in their patients.
A case of invasive mole 44 years P 10 lady underwent TAH with BSO for persistent vaginal bleeding and not declining serum βhCG (preevacuation state >150,000 mIU/ml) following which serum βhCG declined but later increased by 2-fold, received MTX-FA (low risk score 5) completed six cycles and responding well. Shrivastava 19 reported TAH in seven patients of low risk and two in high risk patients for different reasons. May et al. 2 reported 32 patients with low risk GTN treated with hysterectomy and chemotherapy. A hysterectomy may be considered in low risk GTN to reduce multiple doses of chemotherapeutic agents.
Of the 13 low risk GTN cases, majority 4(30.7%) of them achieved remission with two cycles MTX-FA and out of five cases of Act-D, most of them i.e. three achieved remission with two cycles. Two high risk GTN patients treated with EMA-CO achieved remission with four and eight cycles of chemotherapy each. This is comparable with a study conducted by Shivastava et al. 19 where the low risk patients treated with MTX achieved remission after one cycle, those who were treated with Act-D achieved remission after three cycles and in high risk patients treated with EMA-CO, ten patients achieved remission after three cycles and six patients achieved remission after six cycles.
CONCLUSIONS
The most common presentation of GTD was vaginal bleeding. Low risk GTN achieved 65% remission with Methotrexate-Folinic acid, ultimately achieved 100% remission with Actinomycin-D. High risk GTN achieved 100% remission with EMA-CO regimen.
